• The Journal of Korean Obstetrics and Gynecology
• /
• v.26 no.4
• /
• pp.82-93
• /
• 2013

Purpose: The aim of this study was to investigate the relation between peripheral blood leukocyte differential - Granulocyte rate, Lymphocyte rate and its calculated Granulocyte/Lymphocyte ratio - and the obstetric variables. Methods: From 270 cases of women who were in the postpartum care center attached to Won-Kwang Korean Medical Hospital, 36 cases met exclusion criteria. On the obstetric variables of 234 cases, peripheral blood leukocyte differential - Granulocyte rate, Lymphocyte rate and its calculated Granulocyte/Lymphocyte ratio - was analyzed. In the postpartum care center, the obstetric variables were asked of 234 cases of women, and who measured leukocyte differential. Results: Mean granulocyte rate and lymphocyte rate of peripheral blood leukocyte differential showed statistically significant difference from those in healthy people and was high. There was statistically significant difference in granulocyte/lymphocyte ratio according to mood of delivery, parity and period passed from childbirth. But whether postpartum women with anemia or not, maternal age and gender of neonate were not associated with granulocyte/lymphocyte ratio, and which was not significantly correlated with gestational age and neonatal birth weight. Conclusions: These findings suggest that activation of the sympathetic nervous system in postpartum women is higher than in healthy people. And granulocyte/lymphocyte ratio was influenced by mood of delivery, parity and period passed from childbirth. In future, more studies or surveys, with less bias, for the relation between peripheral blood leukocyte differential and the obstetric variables are required.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.24 no.3
• /
• pp.98-108
• /
• 2011

Objectives: The purpose of this study is to investigate the relationship between granulocyte/lymphocyte ratio and dysmenorrhea, history of gynecological disease, heart rate varibility(HRV). Methods: From May 1st 2011 to July 10th 2011, a total of 40 female subjects (age 20-39) were recruited. We evaluated the menstruation condition by questionnaires including VAS(Visual Analog Scale), VRS(Verbal Rating Scale) and MVRS (Multidimensional Verbal Rating Scale), also measured subject's WBC differential count and HRV. Results: 1. There was no statistically significant difference in granulocyte/lymphocyte ratio according to menstruation cycle, duration, amount, color, and blood clot. 2. There was no statistically significant difference in VAS, VRS, MVRS mean scores between normal group and abnormal group according to granulocyte/ lymphocyte ratio. 3. The past prevalence of gynecological disease of abnormal group showed significantly higher compared with that of normal group($x^2$=6.578, p=0.010). 4. LF/HF ratio and granulocyte ratio significantly showed positive correlation ($r_s$=0.311 p=0.048) and LF/HF ratio and lymphocyte ratio significantly showed negative correlation($r_s$=-0.319 p=0.045). Conclusion: These findings suggest that the gynecologic diseases are related to disorder of autonomic nervous system, but not dysmenorrhea. And the balance state of sympathetic/parasympathetic nerve infered through granulocyte/lymphocyte ratio and HRV seems to be consistent. However, reconfirmation through further studies is needed.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.24 no.4
• /
• pp.95-104
• /
• 2011

Objectives: The purpose of this study is to investigate the relationship between the degree of menopausal symptom and granulocyte/lymphocyte ratio, and heart rate varibility(HRV). Methods: From 11th April 2011 to 20th May 2011, a total 30 female subjects (age 41-60) was recruited. We evaluated the degree of menopausal symptoms by Kupperman' s index and measured subject's WBC differential count and HRV. The data were analyzed by Kruskal-Wallis test and Spearman correlation test using SPSS/PC ver 13.0 program. Results: 1. There was no statistically significant difference in granulocyte/lymphocyte ratio and HRV among 4 classified groups according to Kupperman's index.- Mild, Moderate, Severe and Urgent. 2. Granulocyte ratio and general symptom score(within Kupperman's index) significantly showed negative correlation coefficient(r=-0.499, p=0.005), and Lymphocyte ratio and general symptom score significantly showed positive correlation coefficient (r=0.374, p=0.042). 3. Granulocyte/lymphocyte ratio and HRV showed no significant correlation. Conclusions: There was no significant relation among the degree of menopausal symptoms and granulocyte/lymphocyte ratio, and HRV. But furthermore large scale study is required.

• Tuberculosis and Respiratory Diseases
• /
• v.87 no.1
• /
• pp.22-30
• /
• 2024

Tumor immune evasion is a complex process that involves various mechanisms, such as antigen recognition restriction, immune system suppression, and T cell exhaustion. The tumor microenvironment contains various immune cells involved in immune evasion. Recent studies have demonstrated that granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) induce immune evasion in lung cancer by modulating neutrophils and myeloid-derived suppressor cells. Here we describe the origin and function of G-CSF and GM-CSF, particularly their role in immune evasion in lung cancer. In addition, their effects on programmed death-ligand 1 expression and clinical implications are discussed.

• Biomolecules & Therapeutics
• /
• v.6 no.4
• /
• pp.400-405
• /
• 1998

The pharmacokinetics of CJ-50001 (recombinant human granulocyte-colony stimulating factor, developed by R&D center of Cheil Jedang Corp.) were investigated in rats and dogs. The serum concentrations of CJ-50001 were measured by a sandwich enzyme immunoassay. After single intravenous (iv) administration of Cf-50001 to rats at a dose of 5 $\mu$g/kg, the mean terminal half-life and area under the concentration-time curve (AUC) were 0.96 h and 124.497g . h/ml, respectively. After single subcutaneous (sc) administration at the same dose, maximum serum concentration was observed at about 2 hours after administration, and the mean terminal half-life, AUC and the bioavailability were 1.11 h,63.58$\mu$g . h/ml and 51.07%, respectively. In repeated dosing studies, CJ-50001 was administered iv and sc to rats at a daily dose of 5$\mu$g/kg for 7 days. The pharmacokinetic parameters, such as mean AUC and terminal half-life, were no significantly different from those of single administration. Following single iv and sc administration of CJ-50001 to dogs at a dose of 5 $\mu$g/kg, mean AUCs were much higher than those of rats, due to the decreased clearence (CL). After sc administration to dogs, maximum serum concentration was observed at 2~4 hours after administration and the bioavailability was 54.60%.

• Biomolecules & Therapeutics
• /
• v.9 no.4
• /
• pp.311-317
• /
• 2001

YHB6211, a newly developed recombinant human granulocyte colonystimulating factor, was administered at dose levels of 0, 3, 15, and 75 $\mu$g/kg/day intravenously to the pregnant New Zealand White rabbits (20 rabbits per group) during the organogenetic period, days 6 to 18 of gestation. All dams were subjected to Caesarian section on day 28 of gestation and their fetuses were examined for external, visceral, and skeletal abnormalities. No abnormalities in clinical signs, body weight changes, gross findings, mortality, and external appearance were found in all dams and fetuses exposed to 0, 3, and 15 $\mu$g/kg/day of YHB6211. However, in the group treated with 75 $\mu\textrm{g}$/kg/day of YHB6211, maternal body and uterine weights, fetal body weights and length, and the number of live fetuses were significantly decreased and further fetal mortality was remarkably increased. It is suggested that YHB6211 may have no side effect up to the dose level of 15 $\mu$g/kg/day, and there would be no teratogenicity for fetuses of rabbits up to 75 $\mu\textrm{g}$/kg/day even if it may have some toxic effects over 75$\mu\textrm{g}$/kg/day for dams and fetuses of rabbits.

• Biomolecules & Therapeutics
• /
• v.1 no.2
• /
• pp.270-274
• /
• 1993

The acute toxicity of a recombinant granulocyte-macrophage colony stimulating factor (code name: LBD-005) was evaluated in both sexes of ICR mice, 5~6 weeks old, by the oral, subcutaneous and intravenous routes of administration. Based on the results of the acute toxicity study, LBD-005 was not considered to induce any toxic effect on the mice in mortalities, clinical findings, body weights and gross findings. It is suggested that $LD_50$ values in mice would be >48 mg/kg in the oral route and >24 mg/kg in the subcutaneous or intravenous route.

• Toxicological Research
• /
• v.8 no.1
• /
• pp.17-27
• /
• 1992

Antigenicity of Recombinant Granulocyte macrophage colony stimulating factor(LBD-005), a newly developed drug for hematopoietic growth, was investigated in mice and guinea pigs. 1. Mice showed production of antibodies against LBD-005 (100mg/kg) with alumin]m hydroxide gel(alum) as an adjuvant, judged by the heterologous anaphylaxis(PCA) test using rats. On the other hand, antibodies against ovalbumin(OVA) inoculated with alum were definitely detected. 2. In the studies with guinea pigs, both the inoculation of LBD-005 only and of LBD-005 with complete Freund's adjuvant(CFA) as an adjuvant did not produce positive reactions in homologous passive cutaneous anaphylaxis (PCA).

• Toxicological Research
• /
• v.8 no.1
• /
• pp.49-61
• /
• 1992

Recombinant granulocyte-macrophage colony stimulating factor was subcutaneously administered to both sexes of Sprague-Dawley rats at the doses of 0, 0.5, 1 and 2mg/kg of body weight five days per week for 4 weeks to evaluate the subchronic toxicity. There were decreased 1 and 2 mg/kg. In the serum, changes were decreased alkaline phostatase(ALP) in the female groups dosed at 1 and 2mg/kg, and increased glutamic oxaloacetic transaminiase (GOT)in the male groups dosed at 0.5 and 2.0mg/kg.

• Toxicological Research
• /
• v.8 no.1
• /
• pp.41-48
• /
• 1992

The actue toxicity of a recombinant granulocyte macrophage colony-stimulating factor (code name: LBD-005) was evaluated in both sexes of Sprague-Dawley rats, 4 weeks old, by the oral, subcutaneous and intravenous routes of administration. LBD-005 in the acute toxicity study in the rats was not considerde to induce any toxicological effect on the rats in mortalities, clinical findings, body weights and gross findings. It is suggested that $LD_{50}$ values in rats would be >48 mg/kg in the oral route and >12 mg/kg in the subcutaneous or intravenous route.